No Data
No Data
PharmaTher Updated on Its Priority Original Abbreviated New Drug Application for Ketamine
PharmaTher Holdings Ltd. (PHRM.CN), a specialty pharmaceutical company, on Tuesday provided an update on its Priority Original Abbreviated New Drug Application (ANDA) for Ketamine that was accepted by
PharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated...
PharmaTher Provides Update on Its Priority Original Abbreviated New Drug Application For Ketamine
PharmaTher Holdings Ltd. (PHRM.CSE), a commercial-focused specialty pharmaceutical company, on Monday provided an update on its Priority Original Abbreviated New Drug Application (ANDA) for Ketamine t
PharmaTher Provided Update for Expected FDA Approval of Ketamine
PharmaTher Holdings Ltd. (PHRM.CSE) on Wednesday provided an update for its lead drug, ketamine (Ketarx), as a potential treatment for anesthesia, sedation, pain, mental health, and neurological indic
PharmaTher Brief: Notes FDA Assigns GDUFA Goal Date of April 29, 2024
07:34 AM EDT, 09/27/2023 (MT Newswires) -- PharmaTher Brief: Notes FDA assigns GDUFA goal date of April 29, 2024
PharmaTher Brief: Announcing FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)
07:34 AM EDT, 09/27/2023 (MT Newswires) -- PharmaTher Brief: Announcing FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)